Similar to PML-mutated acute promyelocytic leukemias, the abnormal PML-NBs can be targeted with arsenic trioxide in H3.3-mutant pediatric gliomas, and this finding could have clinical applications. Here, PML is linked to acute promyelocytic leukemia.